By Fineline Cube 
Hangzhou Eli Radiopharma Co., Ltd. and Shanghai Smartlogic Technology Ltd. officially signed a strategic cooperation agreement, the companies announced. The two companies will jointly address key R&D pain points in radiopharmaceuticals, deepen collaborative innovation in computation‑driven drug discovery, and co‑build an industry‑competitive cyclic peptide platform.
Deal Overview
| Item | Detail |
|---|---|
| Parties | Hangzhou Eli Radiopharma Co., Ltd. × Shanghai Smartlogic Technology Ltd. |
| Deal Type | Strategic cooperation agreement |
| Signing Date | 22 Jul 2026 |
| Focus Areas | Radiopharmaceutical R&D; computation‑driven drug discovery; cyclic peptide platform |
| Strategic Goal | Address key R&D pain points in radiopharmaceuticals; co‑build an industry‑competitive cyclic peptide platform |
Radiopharmaceutical R&D – Efficient Discovery Closed Loop
In radiopharmaceutical R&D, both parties will target:
- High‑potential existing pipelines
- Novel targets
The collaboration aims to establish an efficient R&D closed loop of:
Computational design → Synthesis → Validation → Optimization
This closed‑loop workflow is designed to accelerate the discovery of clinical candidates that meet downstream development criteria.
Cyclic Peptide Molecular Resource Platform – Co‑Development
Regarding the co‑development of the cyclic peptide molecular resource platform, the partners will leverage a “computation‑driven, highly translatable” physical library of cyclic peptide molecules.
| Element | Detail |
|---|---|
| Foundation | Computation‑driven, highly translatable physical library of cyclic peptide molecules |
| Approach | Collaborative “computational design – synthesis – validation – iteration” cycle |
| Objective | Build a novel cyclic peptide platform with independent intellectual property rights |
Strategic Rationale & Market Impact
- Computation Meets Radiopharma: The partnership pairs Smartlogic’s computation‑driven drug discovery capabilities with Eli Radiopharma’s radiopharmaceutical expertise, directly targeting key R&D pain points in one of oncology’s fastest‑growing modalities.
- Closed‑Loop Acceleration: The “computational design – synthesis – validation – optimization” closed loop is designed to compress discovery timelines and improve the probability that emerging candidates meet downstream clinical development criteria.
- Cyclic Peptide Differentiation: Cyclic peptides occupy a valuable space between small molecules and biologics, offering drug‑like properties with expanded target coverage — a platform asset class with broad partnering potential.
- IP Ownership as Strategic Asset: The explicit goal of building a cyclic peptide platform with independent intellectual property rights signals an intent to create durable, licensable platform value beyond any single program.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the partnership’s research collaboration, platform development, and candidate discovery outcomes. Actual results may differ due to risks including research execution, intellectual property outcomes, and competitive dynamics.-Fineline Info & Tech